Amniotic fluid-derived extracellular vesicles: characterization and therapeutic efficacy in an experimental model of bronchopulmonary dysplasia
Amniotic fluid-derived extracellular vesicles: characterization and therapeutic efficacy in an experimental model of bronchopulmonary dysplasia
复制标题
DOI：
10.1016/j.jcyt.2021.07.011
复制
发表时间：
2021-11-17
期刊：
影响因子：
4.5
通讯作者：
Mitrani, Maria Ines
中科院分区：
文献类型：
--
作者：
Bellio, Michael A.;Young, Karen C.;Mitrani, Maria Ines
背景目的：细胞外囊泡（EVs）作为一种新的治疗方法正在被测试。然而，电动汽车的最佳来源目前正在调查中。羊水（AF）是ev的天然来源，可以很容易地获得用于再生医学，但AF- ev的表征尚未得到充分的探索。方法：本文作者证明AF是ev的丰富来源，并鉴定了microRNA和蛋白质组学货物。生物信息学分析揭示了多种途径靶点，包括免疫调节、抗炎和自由基清除网络。作者进一步证明了EV产品作为支气管肺发育不良（BPD）的新型预防药物的治疗潜力。结果：在实验性BPD模型中，气管内注射af - ev可保护肺泡发育，减轻血管重塑和肺动脉高压，降低肺促炎细胞因子表达，减少巨噬细胞浸润。结论：作者的研究结果表明，AF是一种可行的电动汽车生物液，AF-电动汽车对肺部疾病（如BPD）具有很强的治疗潜力，值得进一步开发，将这种新型电动汽车产品转化为临床产品。(c) 2021年国际细胞与基因治疗学会。Elsevier Inc.出版。版权所有。
Background aims: Extracellular vesicles (EVs) are being tested for their use as novel therapeutics. However, the optimal source of EVs is currently under investigation. Amniotic fluid (AF) is a natural source of EVs that can be easily obtained for use in regenerative medicine, yet AF-EV characterization has not been fully explored. Methods: Here the authors demonstrate AF as a rich source of EVs and identify the microRNA and proteomic cargo. Bioinformatics analysis of this cargo revealed multiple pathway targets, including immunomodulatory, anti-inflammatory and free radical scavenging networks. The authors further demonstrated the therapeutic potential of this EV product as a novel preventative agent for bronchopulmonary dysplasia (BPD). Results: Intra-tracheal administration of AF-EVs preserved alveolar development, attenuated vascular remodeling and pulmonary hypertension, decreased lung pro-inflammatory cytokine expression and reduced macrophage infiltration in an experimental BPD model. Conclusions: The authors' results suggest that AF is a viable biological fluid for EV harvest and that AF-EVs have strong therapeutic potential for pulmonary diseases, such as BPD, warranting further development to transition this novel EV product into the clinic. (c) 2021 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.